PartnerInternational

@PartnerIntl is partnering a brain-penetrant #smallmolecule program targeting primary brain tumors/metastases, with strong preclinical efficacy data, a highly validated target, and a clear development path. Send a DM to learn more. #pharma #biotech #oncology #braincancer #25years

Let’s meet at #BIO2026 in San Diego! Our Executive Team will be on-site and welcomes the chance to connect. We can explore how our global expertise and 25+ years of M&A/licensing experience can support your strategic objectives. Send us a DM to connect! #pharma #biotech #25years

Seeking a US Commercial Partner for a near approval CNS/ADHD product. If you have commercial infrastructure in the market and looking to add new, proprietary products to your portfolio, send @PartnerIntl a DM. #pharma #biotech #25years

@PartnerIntl has completed another transaction on behalf of one of our clients - a regional commercial deal for a late-stage CV asset. If you have BD objectives to partner your pipeline internationally, connect with us to see how we can be of support. #Pharma #Biotech #25Years

Fantastic week at #BIOEuropeSpring in Lisbon, connecting with some of the most innovative teams in biotech and pharma and exploring new BD and partnership opportunities for 2026. If we did not meet, let’s connect soon to discuss your BD priorities. #pharma #biotech #25years

@PartnerIntl is seeking marketed products in specialist indications in the US/CAN for licensing/acquisition for an in-market client with strong commercial capabilities. If you have products available for a strategic transaction, please send us a DM. #pharma #biotech #25years

@PartnerIntl is representing a leading EU CDMO, focusing on next-generation RNA products, preclinical/clinical drug development, GMP-grade mRNA LNP/liposomal formulation, & sterile manufacturing. If you have a pipeline in this area, we should connect! #pharma #biotech #25years

@PartnerIntl invites you to meet our SVP Mark Regular #BIOEuropeSpring in Lisbon, to discuss how we can help you meet your BD objectives. We can explore how our relationships, 25+ years of experience, & track record can accelerate your transactions. Send a DM! #Biotech #25years

@PartnerIntl is partnering a CD22 targeted CAR-T therapy for B-Cell Malignancies. This novel CD22-CAR has activity as stand-alone and in a bi-specific setting. It is available as a fully-validated product, a CAR molecule, or a binder. DM to learn more. #pharma #biotech #25years

@PartnerIntl is pleased to welcome Dr. Jain Stephen to the team as a BD Associate. Jain leverages a strong blend of scientific training and commercial acumen to support clients worldwide. She will work closely with our clients to execute their BD initiatives globally.

Happy Holidays from the Team at Partner International! #pharma #biotech #25years

Meet with the @PartnerIntl Executive team during #JPMWEEK or at BIO Partnering™ @JPM Week 2026! Send a DM to learn how we can help you meet your 2026 BD objectives with our global team, 25+ years of transaction history, and a proven, customized BD approach! #JPM26 #25years

Will you be at BIO@JPM or in San Francisco for JPM Week? We will be and we’d love to connect! Whether you’re curious about partnering, licensing, or M&A opportunities, or want to see how our global network and 25+ years of experience can help you hit your 2026 goals, let’s chat!

What an excellent week at #BIOEUROPE in Vienna! Spent the week connecting with some of the most innovative minds in #biotech & #pharma, diving deep into BD and partnering for 2026. ​If we missed each other during the event, let’s connect soon and explore your BD goals! #25years

@PartnerIntl is out-licensing a preclinical, brain-penetrant small molecule for brain cancers and brain metastases. The program has robust preclinical data, a well-validated target, as is ready for the clinical in the short term. DM to learn more. #pharma #biotech #25years

Will you be at #BIOEUROPE in Vienna? We’d love to meet! Our Team is attending and if you want to explore opportunities in partnering, licensing, or M&A, or want to learn how our global network and #25years of experience can help you reach your goals, let’s talk! Send us a DM!

@PartnerIntl invites you to meet SVP Mark Regular at #MedTechCon in San Diego, to discuss how we can help you meet your BD goals. We can explore how our relationships, 25+ years experience, & track record can benefit you. Send us a DM to connect! #Medtech #Biotech #MTC25 #25years

@PartnerIntl is representing a multinational pharma in their out-licensing of two early stage CD40 and OX40 programs targeting immunology and autoimmune indications. If you are looking to add to your portfolio in these areas, send a DM to learn more. #pharma #biotech #25years

@PartnerIntl is actively seeking marketed products in the US on behalf of a prestigious pharma with robust commercial capabilities. If you have products that fit this profile and you are interested in exploring a strategic partnership, please send a DM #Pharma #Biotech #25Years

@PartnerIntl is evaluating Parkinson’s Disease and GAD programs for global in-licensing. We are evaluating programs at all stages of development, so if you are developing programs in these areas and are seeking a partner, send us a DM. #pharma #biotech #licensing #25years